



Exelixis Announces May 28 Webcast to Discuss New Collaboration Focused on PI3K Program

May 28, 2009

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 28, 2009-- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold a webcast today, May 28, 2009, from 8:00 a.m. ET / 5:00 a.m. PT to 9:00 a.m. ET / 6:00 a.m. PT. Exelixis management will discuss a new collaboration focused on the company's PI3K program.

The webcast may be accessed in the Event Calendar page under Investors at <http://www.exelixis.com>.

An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on June 28, 2009. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is: 99986102.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

Source: Exelixis, Inc.

Exelixis, Inc.

Investor:

Charles Butler, 650-837-7277

Executive Director, Corporate Communications

cbutler@exelixis.com

or

Exelixis, Inc.

Media:

Soleil Maxwell Harrison, 650-837-7012

Senior Manager, Corporate Communications

sharrison@exelixis.com